title: Discriminant analysis of the metabolic effects of a new combined contraceptive vaginal ring containing Nestorone/EE vs. a second-generation oral contraceptive containing levonorgestrel/EE.
abstract: BACKGROUND
  Discriminant analysis (DA) was performed on data of two combined hormonal contraceptives (CHC) differing in estrogen ratio to explore whether a combination of variables rather than a single variable distinguishes CHCs better.
  
  
  METHODS
  Data were used of a parallel study in premenopausal women treated for three cycles (21 days on, 7 days off) with a contraceptive vaginal ring delivering Nestorone and ethinyl estradiol (EE) or an oral contraceptive containing levonorgestrel and EE. DA was performed on the change from baseline (CFB) and the end-of-treatment values at 3 months for lipids, sex-hormone binding globulin (SHBG), C-reactive protein, angiotensinogen, blood pressure and hemostasis variables, and on the hemostasis variables only.
  
  
  RESULTS
  For the complete set, the CFB for factor VII (FVII), SHBG and plasminogen (PLG), or end-of-treatment SHBG- and FVII level discriminated the treatments best. Maximal discrimination for the hemostasis data was by CFB for FVII and PLG or end-of-treatment FVII level.
  
  
  CONCLUSIONS
  DA identifies differences between CHCs and may provide information on the factors associated with thrombotic risk.
authors.affiliation: Centre for Human Drug Research 2333CL, Leiden, The Netherlands.
authors.forename: Mandana
authors.initials: M
authors.lastname: Rad
authors.forename: Jacobus
authors.initials: J
authors.lastname: Burggraaf
authors.forename: Marieke L
authors.initials: ML
authors.lastname: de Kam
authors.forename: Adam F
authors.initials: AF
authors.lastname: Cohen
authors.forename: Cornelis
authors.initials: C
authors.lastname: Kluft
mesh_terms: D000808:Angiotensinogen / Q000187:drug effects / Q000378:metabolism; D001779:Blood Coagulation Factors / Q000187:drug effects*; D001794:Blood Pressure / Q000187:drug effects*; D002097:C-Reactive Protein / Q000187:drug effects* / Q000378:metabolism; D008076:Cholesterol, HDL / Q000187:drug effects / Q000378:metabolism; D008078:Cholesterol, LDL / Q000187:drug effects / Q000378:metabolism; D003274:Contraceptive Devices, Female; D003277:Contraceptives, Oral, Combined / Q000494:pharmacology*; D016002:Discriminant Analysis; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000494:pharmacology*; D005260:Female; D006801:Humans; D016912:Levonorgestrel / Q000494:pharmacology*; D009653:Norprogesterones / Q000494:pharmacology*; D012306:Risk; D012738:Sex Hormone-Binding Globulin / Q000187:drug effects* / Q000378:metabolism; D013927:Thrombosis / Q000139:chemically induced / Q000453:epidemiology; D014280:Triglycerides / Q000378:metabolism
chemical_list: D001779:Blood Coagulation Factors; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D009653:Norprogesterones; D012738:Sex Hormone-Binding Globulin; D014280:Triglycerides; C072593:ethinyl estradiol, levonorgestrel drug combination; D000808:Angiotensinogen; D004997:Ethinyl Estradiol; D016912:Levonorgestrel; C029167:ST 1435; D002097:C-Reactive Protein